Canopy Growth (CGC) Non-Current Debt (2017 - 2026)
Canopy Growth (CGC) posted Non-Current Debt of $158.3 million for Q1 2026, down 1.87% sequentially from $161.3 million in Q4 2025, and down 24.22% YoY from $208.9 million in Q1 2025.
Canopy Growth (CGC) Non-Current Debt (2017 - 2026) Analysis & Trends
Canopy Growth has reported Non-Current Debt for 10 years, with the latest figure at $158.3 million in Q1 2026.
- Quarterly Non-Current Debt fell 24.22% year-over-year to $158.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $158.3 million (down 24.22% YoY) and the FY2026 annual result came in at $158.3 million, down 24.22% from the prior year.
- Non-Current Debt slipped to $158.3 million in Q1 2026 per CGC's latest filing, from $161.3 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $1.2 billion in Q1 2022 and troughed at $158.3 million in Q1 2026.
- A 5-year average of $459.2 million and a median of $382.5 million in 2023 frame the typical range for Non-Current Debt.
- The widest YoY moves for Non-Current Debt: up 5.25% in 2022, down 53.4% in 2022.
- Over 5 years, Non-Current Debt stood at $552.6 million in 2022, then slumped by 30.78% to $382.5 million in 2023, then dropped by 17.95% to $313.8 million in 2024, then sank by 48.59% to $161.3 million in 2025, then retreated by 1.87% to $158.3 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $158.3 million, $161.3 million, and $164.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Canopy Growth | 437.04 Mn | 190.03 Mn | 16.08 Mn | 152.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.81 Mn |
| Mar 31, 2026 | 158.33 Mn |
| Dec 31, 2025 | 161.34 Mn |
| Sep 30, 2025 | 164.46 Mn |
| Jun 30, 2025 | 208.57 Mn |
| Mar 31, 2025 | 208.94 Mn |
| Dec 31, 2024 | 313.83 Mn |
| Sep 30, 2024 | 304.90 Mn |
| Jun 30, 2024 | 408.33 Mn |
| Mar 31, 2024 | 366.08 Mn |
| Dec 31, 2023 | 382.50 Mn |
| Sep 30, 2023 | 470.85 Mn |
| Jun 30, 2023 | 589.70 Mn |
| Mar 31, 2023 | 554.77 Mn |
| Dec 31, 2022 | 552.61 Mn |
| Sep 30, 2022 | 791.38 Mn |
| Jun 30, 2022 | 991.91 Mn |
| Mar 31, 2022 | 1.18 Bn |
| Dec 31, 2021 | 1.19 Bn |
| Sep 30, 2021 | 1.21 Bn |